PureSinse can now begin the production of cannabis oils at its Brampton, Ontario facility. The output of oils, capsules, vape pens, topicals, and sublingual-sprays are slated to be sold in both domestic and global markets. Earlier this year, the Company purchased high-throughput CO2 extraction equipment and completed construction of its extraction facilities. Pure Global now has the capacity to purify, formulate, extract and process to a volume of 10 kg of oil per day, up to 10,000 capsules per hour, 10,000 vape cartridges per hour, and 2,000 (60ml) tincture bottles per hour.

Pure Global is focused on developing quality, non-combustible cannabis extracts for its medical patients, which will be supported and enhanced by the Company’s pharmaceutical formulations team. Formulation, purification, extraction and packaging are carried out in-house to ensure comprehensive mid-process testing for quality assurance purposes.  The Company has recently secured eight new cannabis strains which include high CBD strains and premium craft cultivars, which will soon become available to medical and legal adult use consumers through its online store and provincial retail partners.

Pure Global’s updated cultivation infrastructure is nearing completion and awaiting additional Health Canada approvals to initiate cultivation. While the company awaits, it will continue to source a library of genetics, low-cost, high-quality CBD inputs, and develop differentiated products to service its medical patients and soon to be announced consumer brands.

Nader Gheshlaghi , VP Production and Operations at PureSinse, has been at the forefront of operationalizing what is intended to become a first-class cultivation, extraction, production and processing facility.  Gheshlaghi comments, “We have built internal processes so that the facilities’ staff can be notified about any potential contaminants which ensure a superior level of product quality and consistency.” This also includes auto-notifications about air contaminants and other potential pollutants that can be identified early.

Gheshlaghi also notes that PureSinse has a quality assurance lab with the ability to provide rapid-microbiology testing within 24-48 hours, rather than the usual two-week turnaround time external labs provide. This will greatly speed up processing times for Pure Global’s customers while also reducing production costs.

“We are excited about the next stages of our business as our production systems come online, we solidify our brand position for the medical and consumer channels, and we initiate the scalable manufacturing of various product lines intended for Canadian and international markets,” commented Malay Panchal CEO of PureSinse and Pure Global. “Most exciting are the lines of CBD-based products we are looking to deploy shortly into the medical, cosmetics, and wellness categories, with a view to helping meet the growing demand in Europe and additional countries as they come online,” added Mr. Panchal.